Trials / Completed
CompletedNCT04783311
Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults
A Phase 1/2 Dose-exploration, Randomized, Observer-blind, Placebo-controlled Study to Determine Safety, Tolerance and Immunogenicity of EuCorVac-19, a Recombinant Protein Vaccine, for the Prevention of COVID-19 in Healthy Adults
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 279 (actual)
- Sponsor
- EuBiologics Co.,Ltd · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
Phase I/II study to determine safety, tolerance and immunogenicity of EuCorVac-19, a recombinant protein vaccine, for the prevention of COVID-19 in healthy adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EuCorVac-19 | Two intramuscular doses (0.5mL per dose) at 3-week interval |
| OTHER | Normal Saline | Two intramuscular doses (0.5mL per dose) at 3-week interval |
Timeline
- Start date
- 2021-02-23
- Primary completion
- 2021-10-15
- Completion
- 2022-09-27
- First posted
- 2021-03-05
- Last updated
- 2023-05-19
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04783311. Inclusion in this directory is not an endorsement.